In that context, the importance of therapeutically correcting immunosuppressive barriers in cancer patients has been recently highlighted by the impressive clinical results of immune checkpoint blockade using monoclonal antibodies against CTLA-4 and PD1/PDL144. Here, CTLA4 is linked to cancer.